December 2007 Briefing - Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for December 2007. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Dermatomyositis Diagnosis Varies By Medical Specialty
FRIDAY, Dec. 28 (HealthDay News) -- Dermatomyositis patients may receive different diagnoses depending on whether they're seen by a dermatologist or rheumatologist, and also according to the degree of their disease, researchers report in the December issue of the Journal of the American Academy of Dermatology.
Abstract
Full Text (subscription or payment may be required)
Interferon Signaling Useful Target in Mouse Lupus
THURSDAY, Dec. 27 (HealthDay News) -- Inhibiting downstream signaling through the interferon-α receptor may reduce the inflammatory response in a mouse model of systemic lupus erythematosus, according to a report published online Dec. 16 in Nature Immunology.
Abstract
Full Text (subscription or payment may be required)
FDA Issues New Warning on Fentanyl Skin Patch
FRIDAY, Dec. 21 (HealthDay News) -- Ongoing concerns about the fentanyl transdermal system, which is marketed under the brand name Duragesic and is also available in generic versions, have prompted the U.S. Food and Drug Administration to issue its second safety warning in two years. The FDA's Dec. 21 warning emphasizes the need to exactly follow directions on the product label and patient package insert in order to avoid accidental overdoses.
